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Structured abstract
Background: To date, the clinical utility of coronary computed tomography angiography (CTA)-derived fractional flow reserve (FFR CT ) has been limited to trials and single center experiences. We herein report the incidence of abnormal FFR CT (≤0.80) and the relationship of lesion-specific ischemia to subject demographics, symptoms, and degree of stenosis in the multicenter, prospective ADVANCE registry.
Methods:
One thousand patients with suspected angina having documented coronary artery disease on coronary CTA and clinically referred for FFR CT <30% stenosis. Notably, stenosis 30-49% vs. <30% had an increased likelihood of ischemia (OR 3.74, 95%CI 1.52-9.17, p<0.0001).
Conclusions:
In this real-world registry, CT angiographic stenosis severity in addition to baseline cardiovascular risk factors conferred an increased likelihood of an abnormal FFR CT . Importantly, however, mild CT angiographic stenoses were noted to have an increased hazard for ischemia and the converse holding true for more severe stenoses as well. Previous randomized studies have shown that stable coronary artery disease (CAD) patients gain a benefit from FFR-guided treatment strategy when compared to angiography-guided treatment strategy. [1] [2] [3] Thus, currently, physiologic assessment by fractional flow reserve (FFR) at the time of invasive coronary angiography (ICA) is considered the gold standard method to identify hemodynamically significant stenosis, inducing ischemia, and justifying revascularization. 4 Anatomic assessment by coronary computed tomography angiography (CTA) has emerged as a noninvasive method for direct visualization of CAD, demonstrating high diagnostic performance. 5, 6 Coronary lesions with a stenosis severity of ≥50% on visual coronary CTA are generally considered for referral to ICA. 7 Coronary CTA, however, may result in both underestimation and overestimation of a lesion's severity and is often inaccurate in identifying lesions that cause ischemia. 7, 8 Thus, the ideal test for assessing suspected obstructive CAD should yield both anatomic and physiologic information regarding administration of hyperemic agents such as adenosine. 9 Three prospective multicenter trials have demonstrated that FFR CT accurately predicts the hemodynamic significance of a coronary stenosis when compared to invasively measured FFR and the availability of FFR CT data in addition to coronary CTA provides a markedly improved diagnostic performance in comparison with stenosis assessment according to coronary CTA alone. 10-12 FFR CT has been shown to have strong clinical utility in recent clinical trials (PLATFORM) and multiple single center studies of patients with stable CAD. [13] [14] [15] In fact, deferring ICA in patients with an FFR CT value of >0.8 had a favorable short-term prognosis (no cardiac events during a median follow-up period of 12 months). [13] [14] [15] To date, however, the clinical utility of FFR CT has been limited to trials and single center experiences.
Hence, we conducted the Assessing Diagnostic Value of Non-invasive FFR CT in Coronary Care (ADVANCE) registry to observe the "real-world" utility and impact of FFR CT on clinical decision-making, outcomes and resource utilization in a broad variety of healthcare settings, regions and patient subsets. 16 We herein report the incidence and predictors of lesion-specific ischemia by FFR CT from the results of the first 1,000 patients enrolled in the ADVANCE registry.
Methods
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Study design and population
The ADVANCE registry is a multicenter, prospective registry that will enroll 5,000 patients with suspected stable symptomatic CAD diagnosed by coronary CTA from 38 sites in Europe, North America and Asia. Patients with prior revascularization were not included in the registry. The rationale, design and goals of this registry have previously been described. 16 The primary endpoint of the registry is the rate of reclassification between the management plan on the basis of coronary CTA alone versus coronary CTA plus FFR CT data. In the present study, we report the results of the first 1,000 patients enrolled from July 14 th , 2015 to June 15 th , 2016. CTA data sets were submitted for FFRct analysis based on the clinical decision of the interpreting physician but it required confirmation of CAD and a focal >25% stenosis.
Clinical and demographic information, medical history, and cardiovascular risk factors (hypertension, hyperlipidemia, diabetes, body mass index [BMI] > 30 kg/m 2 , current smoking, and being male) were prospectively collected.
The study protocol was designed by the steering committee and approved by the institutional review board at each site, and the subjects gave written informed consent prior to participation.
Image acquisition and analysis for CT
Coronary CTA was performed on 64-or higher detector row scanners at each site.
Sublingual nitrates were administered prior to scanning in all patients. If necessary, beta-blockers were orally or intravenously administered targeting a heart rate <60 beats per minute. The protocol for coronary CTA image acquisition was recommended to comply with the Society of Cardiovascular Computed Tomography (SCCT) guideline. 17 Assessment of luminal diameter stenosis was performed using an 18-segment coronary model 17 ; the strategy of stenosis quantification was left to the discretion of the local investigator at each site. Vessel segments ≥2mm in diameter were evaluated for luminal narrowing, and the per-vessel maximum stenosis was categorized as 0%, 1% to 29%, 30% to 49%, 50% to 70%, 71% to 90%, or >90%. Non-evaluable (n=8) or occluded (n=15) vessel segments were excluded from analysis.
FFR CT analysis
Standard coronary CTA datasets were submitted to HeartFlow (Redwood City, CA, USA) for analysis. The FFR CT results were made available to the interpreting physician within 48 h for evaluation and treatment planning of each subject provided that coronary CTA image quality was acceptable for analysis. The scientific basis behind the computation of FFR CT have been described in detail in previous reports. 9-12 FFR CT was displayed for each point in the coronary tree. The lowest FFR CT 
Statistical analysis
Data were reported as mean±SD or number (%). Categorical variables were compared using the chi-square test. To identify independent predictors of abnormal FFR CT (≤ 0.80), clinical and coronary CTA variables were entered into a multivariate logistic regression model if their univariate p value was <0.1. Results were expressed as odds ratios with 95% confidence intervals. A p-value of <0.05 was considered statistically significant. All statistical analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC, USA). . Symptom status and nature is available in Table 1 with the majority having typical (27.7%) and atypical angina (38.2%) with 20.6% being asymptomatic. In patients with typical angina, Canadian Cardiovascular Society grade II angina was most commonly observed.
Results
Patient characteristics
FFR CT
FFR CT results were available in 952 (95.2%) patients. As shown in Table 2 , coronary CTA image quality was not acceptable for FFR CT analysis in 33 (3.3%) patients, and FFR CT was not requested in 15 (1.5%) patients as decision making was made on the basis of CTA.
Rate of FFR CT positivity and relationship to stenosis severity
Overall, 486 (51.1%) of 952 patients had a positive FFR CT value (≤0.80). An abnormal FFR CT was observed in 44.2% of the LAD lesions, 17.7% of the LCX lesions, and 21.9% of the RCA lesions, respectively.
On a per-vessel level analysis, there was a mismatch between the CT angiographic and FFR CT assessments of lesion severity, as shown in Figure 1 . Specifically, FFR CT was ≤0.80 in 742 (32.1%) of a total of 2,315 vessels. Out of 1,282 vessels (55.4% of the total vessels analyzed) categorized as having diameter stenosis < 50%, FFR CT was ≤0.80 in 183 (14.3%). On the contrary, FFR CT was negative for ischemia (>0.8) in 474 (45.9%) of 1,033 vessels categorized as having coronary CTA stenosis severity ≥ 50% diameter stenosis. Importantly, of all vessels with a diameter stenosis of 30% to 49%, 20.8% were below the ischemic threshold (FFR CT ≤ 0.80) and in the category 71% to 90% stenosis, 28.4% were not hemodynamically significant with an FFR CT value over 0.8. Of all vessels having 50% to 70% stenosis, in 382 (58.6%), FFR CT was >0.80 and in 270 (41.4%), FFR CT was ≤0.80. Representative cases are displayed in Figure 2 
Predictors of abnormal FFR CT
The results of univariate analysis for predicting abnormal FFR CT are shown in 43.9%, p=0. 0001). In addition, >70% stenosis vs. <30% stenosis was significantly associated with abnormal FFR CT (OR: 31.16, 95%CI: 12.25-79.22, p<0.0001). Of note, stenosis 30-49% vs. <30% was more likely to have ischemia (OR: 3.74, 95%CI:
1.52-9.17, p<0.0001). Furthermore, there was a trend for more abnormal FFR CT values in LAD lesions (OR: 2.13, 96%CI: 0.74-6.09) in comparison with RCA lesions.
Discussion
The present study investigated the incidence and predictors of lesion-specific ischemia by FFR CT in the ADVANCE registry. The major findings were as follows:
Approximately half of stable patients diagnosed with CAD by coronary CTA were positive for ischemia with an FFR CT value of ≤0.8. Patients having ≥3 risk factors were associated with a significantly higher incidence of abnormal FFR CT than those having fewer than 3 risk factors, with both diabetes and hypertension at baseline being independent predictors of abnormal FFR CT . Interestingly, neither symptom status nor symptom typicality were found to be independent predictors of lesion specific ischemia. Importantly, when analyzed on a per-vessel basis, there was a significant discordance between coronary CTA anatomic stenosis severity and functional stenosis severity Coronary CTA has asserted itself as an important noninvasive imaging tool for patients with symptoms and suspected CAD. 18, 19 It is well established that anatomic imaging by coronary CTA or ICA correlates poorly with functional stenosis severity. 8 Physiologic assessment by FFR CT is a new noninvasive diagnostic method to identify the functional significance of a coronary stenosis from standard coronary CTA images, without the need for modification of acquisition protocols, or administration of a vasodilator. 9 A meta-analysis of 3 FFR CT trials demonstrated its superior diagnostic accuracy compared to coronary CTA alone (area under receiver-operating characteristic curve: 0.89 for FFR CT versus 0.74 for coronary CTA alone) when using invasive FFR assessment as the reference standard. 20 In the present study, of all vessels with a stenosis severity of 50% to 70%, FFR CT indicated 58.6% to be functionally nonsignificant and 41.4% to be functionally significant. Even in more severe stenoses between 71% and 90% CT angiographic stenosis severity, 28.4% of all vessels were negative for lesion-specific ischemia as determined by FFR CT . Our findings are in line with prior large-scale invasive FFR studies of over 1,300 coronary artery lesions demonstrating that 65% of all stenoses with 50%-70% diameter stenosis and 20% of all stenoses with 71%-90% diameter stenosis were not hemodynamically significant (FFR>0.80). 21 In contrast, even in vessels with 30% to 49% stenosis, traditionally M A N U S C R I P T
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15 considered non-causative of ischemia, lesion-specific ischemia (FFR CT ≤ 0.80) was more frequently observed than in vessels with <30% stenosis severity (20.8% vs. 8.7%; OR 3.74, 95%CI 1.52-9.17, p<0.0001). Only in the CT angiographic stenosis categories of >90% and <30% did visual lesion assessment by coronary CTA corresponded well with lesion severity by FFR CT . These findings are consistent with those seen in previous invasive FFR studies. 21, 22 Thus, the initial results from the real-world international ADVANCE registry confirm that there is a visual-functional mismatch between FFR CT and coronary CTA, regarding lesion severity. Consequently, the addition of FFR CT to coronary anatomy from the CTA could lead to significant reclassification of vessels thought to be causal of ischemia when compared with CT alone thereby potentially enabling more appropriate decision-making around invasive assessment and revascularization. 23, 24 The recent FFR CT RIPCORD study reported that the routine availability of FFR CT data disclosed a change in clinical management based on coronary CTA alone in 36% of the patients with stable chest pain. 24 coronary CTA images by site assessment were excluded from enrolling in the registry, 3.3% of patients were judged to have unsuitable coronary CTA images for analysis. This proportion was similar to or lower than that (2%-13%) seen in previous studies. 12, 13, 15 However, we cannot comment on how many additional coronary CTA examinations were not submitted out of concerns for image quality. Second, direct comparison of per-vessel FFR CT to invasively measured FFR was not performed. However, it has already been demonstrated that there is a good correlation between FFR CT values and FFR values. 10,12,15 Third, information regarding other factors including location of stenosis and plaque morphology by coronary CTA, 25,26 which may be related to lesion-specific ischemia, were not collected. Finally, with the early integration of FFR CT , many sites used the nadir FFR CT value per vessel rather than the now more accepted practice of adjudication of lesion-specific ischemia 2 cm distal to a stenosis. 27,28 Future analyses of the entire ADVANCE registry will enable a deeper understanding of which metric is more appropriate to guide decision-making and yield more prognostic information.
Study limitations
Conclusions
In this real-world registry, while CT angiographic stenosis severity conferred an increased likelihood of an abnormal FFR CT , the relationship is not consistent enough to 
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